AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 12:35:25 2026-03-13 pm EDT			5-day change	1st Jan Change
14,380.00 ^GBX	+0.11%		-0.83%	+4.28%

Mar. 12	European Markets in the Red as Concerns Persist
Mar. 12	Abivax Denies Reported Takeover Talks With AstraZeneca	MT

ASTRAZENECA : Bernstein maintains a Buy rating

Published on 02/13/2026 at 05:24 am EST

MarketScreener with dpa-AFX Analyser

ASTRAZENECA PLC

+0.11%

In his latest research note, analyst Justin Smith confirms his positive recommendation. The broker Bernstein is keeping its Buy rating. The target price has been raised to GBX 20500 from GBX 18400.

Latest news about AstraZeneca PLC

Mar. 12	European Markets in the Red as Concerns Persist
Mar. 12	Abivax Denies Reported Takeover Talks With AstraZeneca	MT
Mar. 12	Abivax spokesperson denies La Lettre reports
Mar. 12	Abivax Denies La Lettre Report of AstraZeneca Exclusivity	MT
Mar. 12	Abivax Denies La Lettre Report of AstraZeneca Exclusivity, Bloomberg Reports	MT
Mar. 12	Tellus Midas declined 1.30 percent in February - increased cash position	FW
Mar. 12	AstraZeneca in pole position to acquire Abivax
Mar. 12	Ipsen Announces Executive Changes	CI
Mar. 11	Alfred Berg Sverige Gambak rose 4.20 percent in February - sold holdings in Volvo Cars, Camurus and Verisure	FW
Mar. 11	Health Rounds: Death from dementia on the rise among people with type 2 diabetes	RE
Mar. 11	Shares down as Middle East tensions rise	AN
Mar. 10	Lepu Biopharma Says AstraZeneca Begins Phase 3 Trial of CMG901 Cancer Therapy; Shares Jump 7%	MT
Mar. 10	Keymed Biosciences updates on collaboration with AstraZeneca on core product CMG901 (AZD0901)	RE
Mar. 10	Keymed Biosciences Inc. and Astrazeneca AB Receive Milestone Payment Under License Agreement for Cmg901	CI
Mar. 10	Spago Nanomedical AB Appoints Torsten Malmström as Director CMC & Supply and Management Team Member	CI

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).

Employees

96,100

Sector

Pharmaceuticals

Calendar

Apr. 29 - Earnings release - Q1 2026

More about the company